$ASRT

3 stories mentioning ASRTUpdated 33d ago

Every FINWIRES story that references ASRT, newest first.

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.9% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Corcept Therapeutics (CORT) shares rose past 11% after UBS Securities upgraded the stock to buy from neutral and raised its price target to $72 per share from $44.Ironwood Pharmaceuticals (IRWD) fell 10% after the company said Gregory Martini is resigning from his role as chief financial officer, effective May 15.Personalis (PSNL) shares jumped 6% after the firm said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services has expanded coverage for its NeXT Personal minimal residual disease test.Assertio (ASRT) shares rose 3.4% after the company said Wednesday it has agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.

$ASRT$CORT$IRWD$PSNL

Sectors33d ago

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, Personalis (PSNL) shares jumped past 7% after the company said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services expanded coverage for its NeXT Personal minimal residual disease test.Assertio (ASRT) shares rose 3.4% after the company said Wednesday it agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.UroGen Pharma's (URGN) Zusduri treatment demonstrated a 64.5% 36-month duration of response in a pivotal phase 3 trial in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, the company said Wednesday. Its shares rose 1.9%.

$ASRT$PSNL$URGN

Wire42d ago

Assertio's Acquisition Price by Garda Boosted to $21.80 a Share; Stock Surges 17%

Assertio Holdings (ASRT) shares were up more than 17% in recent trading on Monday after the company said the price of its acquisition by Garda Therapeutics has been raised to $21.80 a share from $18 when the deal was announced last month.The amended agreement raises the total acquisition price to $153.2 million from $125.1 millionThe deal is expected to close in Q2, and is subject to customary closing conditions, including the tender of a majority of Assertio's outstanding shares.Following the completion of the tender offer, Garda will acquire any remaining shares through a second-step merger for $21.80 per share in cash. When the deal closes, Assertio's common stock will cease trading on Nasdaq.Price: $21.70, Change: $+3.23, Percent Change: +17.46%

$ASRT